โ† All deals

BIOMARIN PHARMACEUTICAL INC

Public Equity (NASDAQ)BiotechnologyPublic CompanyRare Diseases
๐Ÿ“ San Rafael, CA, United Statesโ€ข Founded 1997
StreetZero Signal 57
Be the first to signal interest

About BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. Founded in 1997 by Christopher Starr and Grant W. Denison Jr., it went public in 1999 and trades on NASDAQ under BMRN. The company is headquartered in San Rafael, CA, operates a B2B model, and maintains social profiles on Facebook, Twitter, and Instagram.

LATEST FUNDINGRule 144
$303K
Announced 2026-11-18
TOTAL RAISED1.82B USD
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for BIOMARIN PHARMACEUTICAL INC.

Free plan includes 3 full deal profiles every month.

Key highlights

  • BioMarin was founded in 1997 with seed investment from Glyko Biomedical and went public in 1999.
  • Total funding reached 1.82B USD with last reported round as post-IPO debt in 2026.
  • Company maintains 239,250 LinkedIn followers and focuses on rare-disease drug development.
  • Acquired Glyko Biomedical in 2002 and has faced criticism over drug pricing practices.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account